Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Oxford BioMedica ( (GB:OXB) ).
Oxford Biomedica announced the successful passing of all resolutions at its Annual General Meeting, including board changes with Stuart Henderson stepping down and Colin Bond and Peter Soelkner assuming new roles. These changes are expected to impact the company’s governance and strategic direction, reinforcing its position in the cell and gene therapy industry.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s overall score reflects strong earnings call outcomes and technical momentum, though constrained by financial performance challenges. Strategic initiatives and revenue growth are positive, but financial leverage and profitability remain concerns.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience in viral vectors, OXB collaborates with leading pharmaceutical and biotechnology companies to provide expertise in viral vector development and manufacturing. The company offers unique technologies for viral vector manufacturing and has facilities in the UK, France, and the US.
Average Trading Volume: 253,463
Technical Sentiment Signal: Sell
Current Market Cap: £353.8M
For a thorough assessment of OXB stock, go to TipRanks’ Stock Analysis page.